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We report a ﬁrst set of peptidomimetic ligands mimicking the
adhesive interface identiﬁed by recent crystallographic structures
of E- and N-cadherin. Compounds 2 and 3 inhibit adhesion of
epithelial ovarian cancer (EOC) cells with improved eﬃcacy com-
pared to the ADH-1 peptide, a N-cadherin antagonist that is in
early clinical trials in EOC patients.
Cadherins are a large family of calcium-dependent cell
adhesion molecules that are mostly expressed at the intercellu-
lar junctions. They are known to play a key role in important
physiological processes such as tissue morphogenesis and
stability, as well as in the immune system regulation. Over the
past 20 years, dysregulation of the type I epithelial E-cadherin
(cadh) and neuronal N-cadh has been shown to correlate with
tumor progression and other pathological processes.1 The
switch in expression from E-cadh to N-cadh is an important
indicator of the epithelial–mesenchymal transition (EMT)
occurring during cancer progression.1 Although E-cadh is con-
sidered a repressor for the majority of carcinomas, in epi-
thelial ovarian cancer (EOC) E-cadh persists during tumor
progression.2 We have shown that E- and N-cadh can be co-
expressed in some advanced-stage EOCs and that E-cadh
expression and homophilic interaction contribute to the pro-
liferation of EOC cells.2
Cadherins from opposing cells interact by means of their
extracellular regions, constituted by five Ig-like domains (EC1–
EC5), and form multiple trans homophilic dimers arranged in
a zipper-like fashion across the cellular adherens junctions.3,4
Several X-ray structures of type I and II cadherin ectodomains5
have shown that trans dimerization occurs through the
opening of the highly conserved N-terminal six-residue portion
of the EC1 (the “adhesion arm”) that contains a Trp residue in
position 2 (Trp2), and its swapping into an acceptor pocket of
the EC1 of the interacting protein, thus resulting in the so-
called “strand dimer” formation. However, the complex and
highly dynamical cadherin dimerization pathway has only
been partially elucidated by the wealth of biochemical and bio-
physical studies performed to date.4 Ultimately, a variety of
transient yet critical key intermolecular interactions involving
diﬀerent residues at diﬀerent stages of the full cadherin dimer-
ization trajectory play all a critical role in guiding the system
through a number of intermediate intermolecular protein–
protein arrangements during the recognition process that
leads from monomeric cadherin to strand-dimer-formation
and back.6
As a result of this highly dynamic behaviour and despite a
growing interest in the field, the rational design of small
ligands targeting cadherin protein–protein interactions is still
in a very early stage. The first crystal structure of the N-cadh
EC1 dimer revealed an association interface characterized by
the His79-Ala80-Val81 (HAV) and the Ile53-Asn54-Pro55 (INP)
sequences and not involving the strand swapping portion of
the molecule.7 This triggered an interest in the synthesis of
libraries of cyclic peptides based on HAV or INP sequences and
of non-peptide HAV mimics for the inhibition of the cadherin
dimerization process.8 Among them, the antagonist peptide
N-Ac-CHAVC-NH2 (ADH-1 or Exherin™, Fig. 1) containing the
HAV motif was promoted to phase I clinical trials in patients
with advanced solid tumors which express N-cadh.9
In this paper, we report the first small library of peptidomi-
metics based on the tetrapeptide sequence Asp1-Trp2-Val3-Ile4
(DWVI) of the N- and E-cadh N-terminal “adhesive arm”. To
the best of our knowledge, this work represents the first
attempt to rationally design small molecules targeting the
strand dimer interfaces identified by recent crystallographic
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structures.5 Our compounds were tested in biochemical and
functional assays on EOC cells for their ability to inhibit both
N- and E-cadh homophilic interactions relative to ADH-1.
About 30 peptidomimetics of general formula NH3
+-Asp-
scaﬀold-Ile-NHCH3 were built in silico by replacing the central
dipeptide Trp2-Val3 unit of the DWVI adhesive motif with
several scaﬀolds developed in our and other laboratories
(Fig. 2).10,11
All the peptidomimetics featured a conformationally con-
strained scaﬀold bearing a benzyl or phenyl ring to mimic the
indole moiety of Trp2 in the native sequence. Based on the
molecular architecture of the scaﬀolds, the aromatic ring was
expected to be diﬀerently oriented into the binding pocket. To
evaluate the ability of each of the compounds of our virtual
library to reproduce the DWVI key interactions observed in
the X-ray dimer structures (Fig. S1†) and during molecular
dynamics simulations (Fig. S2 and S3†), we built a model of
the EC1 fragment of E- and N-cadh starting from the corres-
ponding X-ray structures and set up a docking protocol using
the Glide V5.7 software12 (see ESI†).
Docking results were sorted according to the Glide score
and filtered to match the two most important binding inter-
actions: (i) the formation of an intermolecular salt bridge
between the charged N-terminal amino group of Asp1 and the
side chain carboxylate of Glu89 and (ii) the anchoring of
the Trp2 side chain into a hydrophobic pocket described for
the DWVI motif. Based on this analysis, three ligands were
selected for synthesis and biological assays (Fig. 1).
In the docking poses, all the three ligands form the salt
bridge (i) and insert the scaﬀold benzyl ring into the corres-
ponding hydrophobic pocket of Trp2 (ii). In addition, in the
N-cadh binding site an electrostatic interaction between ligand
Asp1-NH3
+ and the side chain of Asp27 is also observed, while
in E-cadh there is the formation of a hydrogen bond with
Asn27. The main diﬀerence in the binding mode of the three
ligands is related to their 3D alignment with respect to the
DWVI sequence of the crystallographic structures: while 2 and
3 are able to mimic the extended backbone arrangement of the
reference tetrapeptide in both cadherin receptors (see Fig. 3
and S4† for docking results of 3), 1 orients the Ile residue back
to the Asp1 amino acid and does not reproduce the experi-
mental backbone conformation (Fig. S5†).
The three ligands were successfully synthesized using con-
ventional high-yielding synthetic pathways in solution and in
the solid phase (see ESI†).
The compounds were tested by ELISA for their ability to
inhibit calcium-dependent cadherin binding using the
N-cadh-expressing EOC cell line SKOV3 and N-cadh-Fc
chimeric protein. Ligands 2 and 3 at 2 mM concentration
inhibited N-cadh homophilic binding by 78% and 84%,
respectively, and 50% and 65% at 1 mM concentration
(Fig. 4A). Conversely, at 2 mM concentration ADH-1 and 1 pro-
vided about 50% inhibition of N-cadh-Fc/cells interactions and
appeared nearly ineﬀective at 1 mM concentration (Fig. 4A).
The compounds were then evaluated for their ability to inhibit
EOC cells adhesion by observing the formation of cell mono-
layers in the presence of each ligand at 2 diﬀerent concen-
trations (2 and 1 mM). As with ADH-1, at 2 mM concentration
all compounds were able to inhibit the formation of cell mono-
Fig. 1 The N-cadherin antagonist peptide ADH-1 and peptidomimetic
ligands synthesized 1–3.
Fig. 2 Scaﬀolds used for the generation of the virtual library of tetra-
peptide mimics.
Fig. 3 Best pose of 3 (C in grey, N in blue and O in red) into the N-cadh
binding site (blue), overlaid to DWVI (green) of the X-ray dimer.
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layers of N-cadh-expressing cells (Fig. S6†). Notably, 2 and 3
were also active at 1 mM concentration, and 3 was able to
inhibit cell–cell aggregation of N-cadh-expressing cells in sus-
pension (Fig. 4B). When tested on the E-cadh-expressing EOC
cell line OAW42, all compounds were found to be less eﬃcient
in inhibiting both E-cadh homophilic interactions and the for-
mation of cell monolayers, with significant eﬀects observed
only at 2 mM concentration (Fig. S6 and S7†). In particular, by
ELISA, at the concentration of 2 mM 1 and 3 gave about 50%
inhibition of E-cadh-Fc binding to the cells while ADH-1
showed 30% inhibition (Fig. S7†), indicating a slightly better
eﬃcacy compared to ADH-1 in inhibiting also E-cadh homo-
philic interactions. Compound 2 was also able to inhibit the
formation of cell monolayers at 1 mM concentration (Fig. S6†).
Overall, compounds 2 and 3 resulted to be eﬀective in inhi-
biting N-cadh homophilic and, to some extent, also E-cadh
homophilic adhesion. Encouraged by the very promising
results with N-cadh-expressing cells, we set out to evaluate by
surface plasmon resonance (SPR) analysis the ability of the two
compounds to specifically inhibit the N-cadh homo-dimeriza-
tion in a cell-free experiment using the N-cadh-Fc recombinant
protein. At 10 μM concentrations compounds 2 and 3 provided
98% and 55% inhibition of N-cadh homophilic binding,
respectively, while ADH-1 showed only 28% inhibition
(Fig. S8†). These data demonstrate the ability of both com-
pounds 2 and 3 to specifically bind to N-cadh even in the μM
range.
The combination of our computational investigation with
the results of SPR assays has started to shed light on the
ligand structural requirements for binding to N-cadh. For
instance, it appears that the best inhibitors (2 and 3) of N-cadh
homophilic binding maintain the key (i) and (ii) interactions
and also align with the DWVI backbone (Fig. 3). Although
N- and E-cadh share similar adhesive binding features for the
DWVI sequence5 and no significant diﬀerences were observed
in the interaction mode of our peptidomimetic ligands in the
two cadherin docking models, the tests on the E-cadh-expres-
sing EOC cell line OAW42 showed lower inhibition capability
of E-cadh homophilic binding compared with those of N-cadh.
Since a detailed picture of the complete adhesion pathway in
the diﬀerent cadherin family members is still elusive13 and a
variety of factors can contribute to the formation and dis-
sociation of cadherin dimers on cell membranes, our results
can be interpreted in light of diﬀerent considerations. First,
two-dimensional aﬃnities measured by micropipette adhesion
assays on cell lines expressing E- or N-cadhs,4 have shown that
E-cadh homophilic binding is stronger than that of N-cadh.
For this reason, our compounds might be less eﬃcient in inhi-
biting E-cadh than N-cadh interactions. Moreover, based on
compelling structural data,4,5 we decided to focus exclusively
on the inhibition of the swapped-dimer formation targeting
the EC1 domain, although several extracellular domains are
known to be involved in the formation of highly dynamic and
transient protein–protein contacts at the adhesive interface.
It is worth stressing that targeting the interfaces between
proteins has huge therapeutic potential, but it still remains a
challenge to discover small drug-like molecules that are
capable of modulating those protein–protein interactions that
are by their nature highly dynamical. In fact, it is clear that the
dynamic features of the cadherin dimerization process are
likely to play against a traditional drug design approach.
Accordingly, the design of a stable molecular interactor against
the adhesion pocket would not just prove diﬃcult but it would
fail to achieve complete inhibition. However, peptidomimetic
molecules that can transiently interfere with structurally
validated intermediates in the cadherin dimerization pathway
may successfully modulate cadherin-mediated adhesion, even
in the absence of an unequivocal identification of the actual
binding site and mode.
Conclusions
In this work, we report a first set of peptidomimetic ligands
mimicking the adhesive E- and N-cadh DWVI sequence.
Remarkably, two of our peptidomimetics inhibit the N-cadh-
mediated adhesion process in EOC cells with somewhat
improved eﬃcacy compared to the ADH-1 cyclic peptide,
which is being investigated in phase I clinical trials as a
N-cadh antagonist in various tumors, including EOCs.9
Fig. 4 (A) Ligand inhibition of N-cadh-Fc binding to SKOV3 cells by
ELISA. (B) Ligand inhibition of the SKOV3 cell monolayer formation by
adhesion assay. Controls in the absence of ligand in water (left) and in
10% DMSO solution (right) are reported.
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Thus, the small molecules generated in the present study
are likely to represent new leads for the development of a
novel class of modulators of cadherin-mediated adhesion.
Such compounds may play an important role in the investi-
gation of cellular processes, and in the design of novel diag-
nostic and therapeutic approaches against tumors, especially
EOCs. Indeed, since the majority of EOCs grow and dissemi-
nate in the peritoneal cavity, the locoregional administration
of drugs would allow the use of cadherin inhibitors
without interfering with the cadherins expressed in normal
epithelia.
Acknowledgements
We thank Università degli Studi di Milano for PhD Fellowship
to FD and CINECA for computing facilities. We also gratefully
acknowledge Ministero dell’Università e della Ricerca for
financial support to MC (RBFR088ITV project), the AIRC for
the IG13055 grant to AT and the European Union for the
“Marie Curie” FP7-PEOPLE-2010-RG grant to EP (DETACH –
N.268231). We thank Dr Silvana Canevari for the useful
suggestions and support.
Notes and references
1 G. Berx and F. van Roy, Cold Spring Harbor Perspect. Biol.,
2009, 1, a003129; O. W. Blaschuk and E. Devemy,
Eur. J. Pharmacol, 2009, 625, 195.
2 G. De Santis, S. Miotti, M. Mazzi, S. Canevari and
A. Tomassetti, Oncogene, 2009, 28, 1206.
3 J. Brasch, O. J. Harrison, B. Honig and L. Shapiro, Trends
Cell. Biol., 2012, 22, 299.
4 D. Leckband and S. Sivasankar, Curr. Opin. Cell Biol., 2012,
24, 620; J. Vendome, S. Posy, X. Jin, F. Bahna, G. Ahlsen,
L. Shapiro and B. Honig, Nat. Struct. Mol. Biol., 2011, 18,
693.
5 O. J. Harrison, X. Jin, S. Hong, F. Bahna, G. Ahlsen,
J. Brasch, Y. Wu, J. Vendome, K. Felsovalyi,
C. M. Hampton, R. B. Troyanovsky, A. Ben-Shaul, J. Frank,
S. M. Troyanovsky, L. Shapiro and B. Honig, Structure,
2011, 19, 244; E. Parisini, J. M. G. Higgins, J. Liu,
M. B. Brenner and J. Wang, J. Mol. Biol., 2007, 373, 401;
T. J. Boggon, J. Murray, S. Chappuis-Flament, E. Wong,
B. M. Gumbiner and L. Shapiro, Science, 2002, 296, 1308;
S. D. Patel, C. Ciatto, C. P. Chen, F. Bahna, M. Rajebhosale,
N. Arkus, I. Schieren, T. M. Jessell, B. Honig, S. R. Price
and L. Shapiro, Cell, 2006, 124, 1255.
6 Y. Li, N. L. Altorelli, F. Bahna, B. Honig, L. Shapiro and
A. G. Palmer 3rd, Proc. Natl. Acad. Sci. U. S. A., 2013, 110,
16462.
7 L. Shapiro, A. M. Fannon, P. D. Kwong, A. Thompson,
M. S. Lehmann, G. Grübel, J. F. Legrand, J. Als-Nielsen,
D. R. Colman and W. A. Hendrickson, Nature, 1995, 374,
327.
8 E. Williams, G. Williams, B. J. Gour, O. W. Blaschuk and
P. Doherty, J. Biol. Chem., 2000, 275, 4007; G. Williams,
E.-J. Williams and P. Doherty, J. Biol. Chem., 2002, 277,
4361; S. M. Burden-Gulley, T. J. Gates, S. E. L. Craig,
S. F. Lou, S. A. Oblander, S. Howell, M. Gupta and
S. M. Brady-Kalnay, Peptides, 2009, 30, 2380.
9 O. W. Blaschuk, Cell Tissue Res., 2012, 348, 309; A. Perotti,
C. Sessa, A. Mancuso, C. Noberasco, S. Cresta, A. Locatelli,
M. L. Carcangiu, K. Passera, A. Braghetti, D. Scaramuzza,
F. Zanaboni, A. Fasolo, G. Capri, M. Miani, W. P. Peters and
L. Gianni, Ann. Oncol., 2009, 20, 741; N. Yarom, D. Stewart,
R. Malik, J. Wells, L. Avruch and D. J. Jonker, Curr. Clin.
Pharmacol., 2013, 8, 81.
10 L. Manzoni, D. Arosio, L. Belvisi, A. Bracci, M. Colombo,
D. Invernizzi and C. Scolastico, J. Org. Chem., 2005, 70,
4124; A. S. M. Ressurreição, A. Bordessa, M. Civera,
L. Belvisi, C. Gennari and U. Piarulli, J. Org. Chem., 2008,
73, 652; D. Arosio, L. Belvisi, L. Colombo, M. Colombo,
D. Invernizzi, L. Manzoni, D. Potenza, M. Serra,
M. Castorina, C. Pisano and C. Scolastico, ChemMedChem,
2008, 3, 1589; L. Manzoni, L. Belvisi, D. Arosio, M. Civera,
M. Pilkington-Miksa, D. Potenza, A. Caprini,
E. M. V. Araldi, E. Monferini, M. Mancino, F. Podestà and
C. Scolastico, ChemMedChem, 2009, 4, 615; M. Marchini,
M. Mingozzi, R. Colombo, I. Guzzetti, L. Belvisi, F. Vasile,
D. Potenza, U. Piarulli, D. Arosio and C. Gennari, Chem. –
Eur. J., 2012, 18, 6195.
11 Y. Peng, H. Sun and S. Wang, Tetrahedron Lett., 2006, 47,
4769; L. M. Beal, B. Liu, W. Chu and K. D. Moeller, Tetra-
hedron, 2000, 56, 10113.
12 Glide, version 5.7, Schrödinger, LLC, New York, 2011.
13 P. Thiery, W. Engl, V. Viasnoﬀ and S. Dufour, Curr. Opin.
Cell Biol., 2012, 24, 614.
Organic & Biomolecular Chemistry Communication
This journal is © The Royal Society of Chemistry 2015 Org. Biomol. Chem., 2015, 13, 2570–2573 | 2573
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
4 
Ja
nu
ar
y 
20
15
. D
ow
nl
oa
de
d 
on
 0
3/
04
/2
01
5 
09
:5
9:
24
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
